Sterling Capital Management’s Solid Biosciences SLDB Stock Holding History

Sterling Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$14.5K	Buy	2,010 +1,061	+112%	+$9.6K	﹤0.01%	2346
2026 Q2	$9.48K	Sell	949 -1,004	-51%	-$7.61K	﹤0.01%	2250
2026 Q1	$14.1K	Sell	1,953 -1,445	-43%	-$9.28K	﹤0.01%	2191
2025 Q4	$19.2K	Sell	3,398 -670	-16%	-$3.63K	﹤0.01%	2250
2025 Q3	$25.1K	Buy	4,068 +2,286	+128%	+$13.4K	﹤0.01%	2031
2025 Q2	$8.68K	Buy	1,782 +1,409	+378%	+$4.98K	﹤0.01%	2225
2025 Q1	$1.38K	Sell	373 -331	-47%	-$1.42K	﹤0.01%	2710
2024 Q4	$2.82K	Buy	704 +637	+951%	+$3.5K	﹤0.01%	2668
2024 Q3	$467	Buy	+67	New	+$543	﹤0.01%	2906

Other funds holding SLDB

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Quantum Private Wealth Tampa, Florida $391M AUM 50.76% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Physician Wealth Advisors Midvale, Utah $869M AUM 17.6% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Sterling Capital Management's SLDB Position: Q3 2026 in Review

Sterling Capital Management increased its Solid Biosciences (SLDB) stake by 112% in Q3 2026, buying an estimated $9.6K and bringing the position to 2,010 shares worth $14.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2346.

Sterling Capital Management first reported a position in SLDB in Q3 2024 and has held it in 9 quarters since. The position peaked at $25.1K in Q3 2025. 16 funds tracked by Wall St. Rank hold SLDB as of Q3 2026.

Sterling Capital Management held 2,010 shares of Solid Biosciences worth $14.5K as of Q3 2026.
Sterling Capital Management bought 1,061 Solid Biosciences shares in Q3 2026, an estimated $9.6K.
Solid Biosciences made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2346 holding.
Sterling Capital Management first reported a position in Solid Biosciences in Q3 2024 and has held it in 9 quarters since.
Sterling Capital Management's Solid Biosciences position peaked at $25.1K in Q3 2025.
16 funds tracked by Wall St. Rank held Solid Biosciences as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.